# South Korea Antibody Drug Discovery Market

> South Korea Antibody Drug Discovery Market Research Report By Type (Monoclonal Antibodies, Polyclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies), By Technology (Recombinant DNA Technology, Hybridoma Technology, Phage Display Technology, Transgenic Technology), By Application (Therapeutic Applications, Diagnostic Applications, Research Applications) andBy End Use (Pharmaceutical Companies, Biotechnology Companies, Research Institutions) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.94%
- **2024:** $ 169.07 Million
- **2025:** $ 184.18 Million
- **2035:** $ 433.67 Million
- **Key Players:** Roche (CH), AbbVie (US), Amgen (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Sanofi (FR)

**Report ID:** MRFR/Pharma/50163-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-antibody-drug-discovery-market-51921

---

## Market Summary

## **South Korea Antibody Drug Discovery Market Overview**

As per MRFR analysis, the South Korea Antibody Drug Discovery Market Size was estimated at 0.93 (USD Billion) in 2023. The South Korea Antibody Drug Discovery Market Industry is expected to grow from 1.96 (USD Billion) in 2024 to 4.05 (USD Billion) by 2035.

The South Korea Antibody Drug Discovery Market CAGR (growth rate) is expected to be around 6.82% during the forecast period (2025 - 2035).

## **Key South Korea Antibody Drug Discovery Market Trends Highlighted**

The South Korean Antibody Drug Discovery Market is expanding at a phenomenal pace due to new advances made in the field of biopharmaceuticals. The country is also investing heavily in biotechnology and dealing with a lack of innovative therapeutic methods. The government does a lot in terms of supporting local biotech firms by sponsoring research and development projects and providing grants to them, including some in collaboration with schools and universities.

There is strong emphasis placed on the production of monoclonal antibodies which are useful in treating a number of different illnesses from cancer to autoimmune diseases. Possible avenues that can be work on include making use of the well-established information technology infrastructure in South Korea to the implementation of artificial intelligence and machine learning in the medical drug discovery framework.

There are also prospects of using computational methods in speeding up the process of identifying as well as optimizing antibody candidates. Not to mention partnerships of local firms with international biopharma companies for exchange of ideas and materials to foster new development in the discovery and development processes. Some other trends from the South Korea [Antibody Drug Discovery Market](../../../reports/antibody-drug-discovery-market-12055) include increasing focus on tailoring medical care and the drugs used to fit the specific requirements of the individual patient.

This strategy is becoming more important with the transformation of the healthcare industry and the international shift towards more personalized treatments. Additionally, the increase in chronic conditions shifts the focus toward new therapeutic solutions, which antibody therapeutics can provide. These trends and drivers, together with South Korea’s growing global biotechnology leadership, indicate a shift in the country’s antibody drug discovery industry that promotes robust innovation and amplifies competition.

## **South Korea Antibody Drug Discovery Market Drivers**

### **Increasing Investment in Biotechnology Research and Development**

The South Korea Antibody Drug Discovery Market Industry is witnessing significant growth driven by escalating investments in biotechnology Research and Development (R&D). The South Korean government has set a target to increase its biotechnology sector's value to over USD 50 billion by 2026, as part of its 'Bio-Convergence Strategy'. This government initiative has led to increased funding and collaboration opportunities for biotechnology firms and research institutions, stimulating innovation in antibody drug discovery.

Notably, the Korean Ministry of Health and Welfare has reported that public and private investments in R&D have surged by over 25% in the past three years, enhancing the research capabilities required for the development of novel antibody-based therapies, positioning South Korea as a global leader in this space.

### **Rising Incidence of Cancer and Autoimmune Disorders**

The growing incidence of cancer and autoimmune disorders in South Korea is a crucial driver for the South Korea Antibody Drug Discovery Market Industry. The Korean National Cancer Center has reported a significant increase in cancer incidents, with projections indicating that one in three South Koreans will be diagnosed with cancer in their lifetime by 2030.

This alarming trend has spurred increased demand for effective therapeutic solutions, such as monoclonal antibodies, to treat various types of cancers. Moreover, with the prevalence of autoimmune disorders on the rise, there is a critical need for innovative treatments, reinforcing the market growth potential in this segment.

### **Advancements in Antibody Engineering Technologies**

Technological advancements in antibody engineering are propelling the South Korea Antibody Drug Discovery Market Industry forward. Innovative techniques like phage display, hybridoma technology, and recombinant DNA technology are being developed and refined within South Korea, leading to more efficient antibody discovery processes.

South Korean biotechnology firms, in collaboration with academic institutions, have reported breakthroughs in the production of bispecific antibodies and antibody-drug conjugates, enhancing the therapeutic potential and effectiveness of treatments. The Korean Society for Biochemistry and Molecular Biology has highlighted the impressive progress in drug discovery, noting that the number of patents filed in antibody engineering has increased by 30% in the last five years, evidencing the robust growth in this area.

## **South Korea Antibody Drug Discovery Market Segment Insights**

### **Antibody Drug Discovery Market Type Insights**

The South Korea Antibody Drug Discovery Market is characterized by a diverse Type segment, which encompasses various forms of antibodies essential for therapeutic development. Monoclonal antibodies play a crucial role due to their specificity and ability to target specific antigens, making them a primary focus in many therapeutic applications. Their targeted action has made them integral in the treatment of cancers and autoimmune diseases.

Polyclonal antibodies, while less specific, are advantageous in providing a broader response against pathogens, thus serving as valuable tools in both diagnostics and therapeutics. This versatility contributes to their enduring relevance in the antibody drug discovery landscape. Furthermore, Antibody-Drug Conjugates have gained significant traction in recent years, combining the targeting capabilities of monoclonal antibodies with potent cytotoxic agents, ultimately enhancing the efficacy of cancer treatments while minimizing side effects.

Bispecific antibodies are also becoming increasingly important due to their ability to engage two different antigens simultaneously, allowing for innovative treatment strategies in complex conditions. The growing incidence of chronic diseases and an increasing investment in Research and Development by pharmaceutical companies are driving growth across these various types.

This segment is significantly influenced by advancements in biotechnological techniques, leading to the development of more effective and novel therapeutic agents, while regulatory frameworks and collaboration with academic research institutions help to foster a nurturing environment for innovation. As the South Korean government prioritizes biotechnology within its economic strategies, the emphasis on antibody therapies aligns with national healthcare objectives, promoting the growth of the South Korea Antibody Drug Discovery Market segment, ultimately enhancing patient outcomes and advancing therapeutic potentials.

The continuing evolution of this market provides opportunities for companies to leverage their capabilities and strategic partnerships, pushing forward the boundaries of antibody drug development to meet the growing healthcare demands of the region.

### **Antibody Drug Discovery Market Technology Insights**

The Technology segment of the South Korea Antibody Drug Discovery Market plays a pivotal role in advancing therapeutic options. Recombinant DNA Technology is crucial, enabling the development of monoclonal antibodies, which are essential for targeted therapies. This method caters to the growing need for personalized medicine, addressing various diseases and conditions.

Hybridoma Technology remains significant due to its reliability in generating monoclonal antibodies, while Phage Display Technology provides a platform for high-throughput screening of antibody libraries, fostering rapid advancements in drug discovery. Transgenic Technology contributes by producing animals that can produce human antibodies, which are vital for effective treatment solutions.

Collectively, these technologies support a robust pipeline in the antibody drug discovery landscape, driven by increasing investment from governmental initiatives and the private sector in South Korea's biotechnology industry. The market growth in this region is further propelled by an expanding patient population and the rising prevalence of chronic diseases, positioning South Korea as a leader in innovative therapeutic development.

### **Antibody Drug Discovery Market Application Insights**

The South Korea Antibody Drug Discovery Market is experiencing growth driven by its diverse applications across various sectors. The Application segment is critical, encompassing Therapeutic Applications, Diagnostic Applications, and Research Applications, each playing a pivotal role in advancing healthcare. Therapeutic Applications dominate the market as the demand for monoclonal antibodies increases, providing targeted treatments for diseases such as cancer and autoimmune conditions.

Diagnostic Applications are equally significant, with antibody-based testing becoming instrumental in early disease detection and monitoring, especially in the context of infectious diseases and cancers. Research Applications serve as a foundation for innovation, enabling the exploration of new therapies and improving disease understanding through various research initiatives.

The continuous advancement in biotechnology and increasing investment in Research and Development make this segment vital for the growth of the South Korea Antibody Drug Discovery Market. Furthermore, alignment with governmental policies favoring biotechnology advancements enhances opportunities within this sector, positioning South Korea as a competitive player in the global market, with a focus on improving patient outcomes and fostering innovation. Overall, the Application segment reflects the dynamic landscape of biomedical research and therapeutic development in South Korea.

### **Antibody Drug Discovery Market End Use Insights**

The South Korea Antibody Drug Discovery Market showcases a diverse landscape driven primarily by various end-use sectors, namely Pharmaceutical Companies, Biotechnology Companies, and Research Institutions. Pharmaceutical companies are significantly engaged in utilizing antibody drugs to enhance therapeutic efficacy and improve patient outcomes, as the quest for targeted therapies grows in demand.

This segment plays a crucial role in transforming innovative research into market-ready treatments, thus dominating the landscape. Biotechnology companies are also pivotal, focusing on the development of biologics and biosimilars, which are increasingly becoming integral to modern medicine. These companies leverage advances in antibody technology to bring forth novel therapeutics, often catering to unmet medical needs.

Research Institutions contribute to this ecosystem by driving foundational studies and innovations. Their collaborations with industry players foster the development of cutting-edge methodologies in antibody drug discovery, accelerating the journey from bench to bedside. The interplay among these sectors highlights the South Korea Antibody Drug Discovery Market's adaptability and responsiveness to evolving healthcare demands, reflecting the nation's robust emphasis on biopharmaceutical advancements and healthcare innovation.

## **South Korea Antibody Drug Discovery Market Key Players and Competitive Insights**

The South Korea Antibody Drug Discovery Market has gained significant momentum due to advancements in biopharmaceutical research and development, driven by increasing investments in biotechnology and healthcare. This market is characterized by a dynamic environment where innovative companies are striving to develop novel antibody-based therapeutics for various diseases, including cancer and autoimmune disorders.

The competitive landscape in this region is marked by the presence of both established firms and emerging players focusing on enhancing their antibody discovery capabilities through cutting-edge technologies. Factors such as strategic partnerships, collaborations, and mergers are also shaping the competitive dynamics, enabling companies to strengthen their market positions and expand their product offerings.

Y Biologics has carved out a prominent position in the South Korean Antibody Drug Discovery Market, leveraging its expertise in developing tailored antibody therapeutics. The company's focus on innovative drug design and a robust pipeline has made it a key player in the antibody therapeutics space. Y Biologics thrives on its cutting-edge discovery platforms, which facilitate the efficient development of high-affinity antibodies.

The company's strategic collaborations with academic and research institutions further bolster its research capabilities and allow for the translation of scientific discoveries into viable therapeutic solutions. The strength of Y Biologics lies in its specialized knowledge in antibody engineering, combined with a deep understanding of disease biology, enabling the company to address unmet medical needs within the South Korean market effectively.

LG Chem, a powerhouse in South Korea's biopharmaceutical industry, plays a significant role in the Antibody Drug Discovery Market through its comprehensive R&D resources and expertise in biochemistry. The company is particularly known for its commitment to innovation, focusing on monoclonal antibodies and targeted therapies for specific diseases, including cancer and other severe health conditions.

LG Chem has successfully integrated advanced bioprocessing technologies with its existing research capabilities, allowing for the streamlined development of high-quality antibody drugs. Moreover, its strategic mergers and acquisitions have expanded its portfolio, enhancing its research and production capabilities. The company’s prominent presence in the market is underscored by its extensive collaborations with research institutions and frontline clinical studies, which further demonstrate its commitment to advancing healthcare within the South Korean ecosystem.

### **Key Companies in the South Korea Antibody Drug Discovery Market Include**

## **South Korea Antibody Drug Discovery Market Industry Developments**

Recent developments in the South Korea Antibody Drug Discovery Market illustrate significant advancements and collaborations among key players. Y Biologics has accelerated its research timelines, focusing on innovative antibody therapies that target autoimmunity and cancer. LG Chem is advancing its pipeline with a strong emphasis on partnerships, notably in co-developing antibody-drug conjugates.

Celltrion has made headlines with promising preliminary results from clinical trials of its bispecific antibody for the treatment of various cancers. KNC Therapeutics is pursuing unique approaches, building strong developmental ties in the local market. In terms of mergers and acquisitions, Samsung Biologics has strategically acquired a start-up to bolster its research capabilities, while Hanmi Pharmaceutical has entered a collaboration with a U.S.-based company to expand its global footprint in antibody discovery.

Market growth has been notably driven by increased funding and government support for biopharmaceutical innovations, with the Ministry of Health and Welfare investing heavily in biotechnology initiatives. Key companies are witnessing elevated market valuations as the sector rapidly evolves, underscoring South Korea's commitment to becoming a leader in antibody drug innovation.

## **South Korea Antibody Drug Discovery Market Segmentation Insights**

### **Antibody Drug Discovery Market Type Outlook**

### **Antibody Drug Discovery Market Technology Outlook**

### **Antibody Drug Discovery Market Application Outlook**

### **Antibody Drug Discovery Market End Use Outlook**

- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutions

## Market Drivers

### Advancements in Biotechnology

Technological advancements in biotechnology are significantly influencing the antibody drug-discovery market in South Korea. Innovations such as CRISPR gene editing, high-throughput screening, and next-generation sequencing are enhancing the efficiency and accuracy of antibody development. These technologies enable researchers to identify and optimize potential therapeutic candidates more rapidly, thereby reducing the time and cost associated with drug development. Furthermore, the South Korean biotech sector is witnessing substantial investments, with the government allocating over $1 billion to support biotech research initiatives. This influx of funding is likely to accelerate the discovery of novel antibodies, thereby expanding the therapeutic options available in the market.

### Supportive Government Policies

Supportive government policies play a pivotal role in shaping the antibody drug-discovery market in South Korea. The government has implemented various initiatives aimed at fostering innovation and collaboration within the biotech sector. For instance, the establishment of the Korean Biotech Strategy aims to enhance the competitiveness of the industry by providing funding, tax incentives, and regulatory support for biotech companies. These policies are designed to streamline the drug approval process and encourage public-private partnerships, thereby facilitating the development of new antibody therapies. As a result, the antibody drug-discovery market is likely to benefit from an increasingly favorable regulatory environment, which could lead to accelerated product development and commercialization.

### Growing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases in South Korea is a critical driver for the antibody drug-discovery market. Conditions such as cancer, diabetes, and cardiovascular diseases are becoming increasingly common, necessitating the development of effective therapeutic solutions. According to recent health statistics, cancer is the leading cause of death in South Korea, with over 200,000 new cases diagnosed annually. The rising prevalence of chronic diseases has prompted healthcare providers and researchers to seek innovative treatments, including monoclonal antibodies, which have shown promise in improving patient outcomes. Consequently, the antibody drug-discovery market is expected to expand as stakeholders respond to the urgent need for effective therapies targeting these chronic conditions.

### Increasing Demand for Targeted Therapies

The antibody drug-discovery market in South Korea is experiencing a notable surge in demand for targeted therapies. This trend is driven by the growing recognition of the limitations of traditional therapies, which often lack specificity and can lead to adverse effects. Targeted therapies, particularly those utilizing monoclonal antibodies, are perceived as more effective and safer options for treating various diseases, including cancer and autoimmune disorders. The South Korean government has been promoting R&D in this area, with funding initiatives aimed at fostering innovation. As a result, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 10% over the next five years, reflecting the increasing focus on precision medicine within the antibody drug-discovery market.

### Rising Awareness of Personalized Medicine

There is a growing awareness of personalized medicine among healthcare professionals and patients in South Korea, which is significantly impacting the antibody drug-discovery market. Personalized medicine, which tailors treatment based on individual patient characteristics, is gaining traction as a more effective approach to healthcare. This shift is prompting researchers to focus on developing antibodies that can be customized to target specific biomarkers associated with various diseases. The South Korean healthcare system is increasingly adopting this model, with initiatives aimed at integrating personalized treatment options into clinical practice. As a result, the antibody drug-discovery market is expected to expand as more stakeholders recognize the potential benefits of personalized therapies.

## Future Outlook

The [Antibody Drug Discovery Market](https://www.marketresearchfuture.com/reports/antibody-drug-discovery-market-12055) is projected to grow at an 8.94% CAGR from 2025 to 2035, driven by technological advancements and increasing R&D investments.

**New opportunities:**

- Development of personalized antibody therapies for niche markets.
- Expansion of partnerships with biotech firms for innovative drug candidates.
- Investment in AI-driven platforms for accelerated antibody discovery.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biopharmaceutical innovation.

## Segment Insights

### By Type: Monoclonal Antibodies (Largest) vs. Antibody-Drug Conjugates (Fastest-Growing)

In the South Korea antibody drug-discovery market, Monoclonal Antibodies dominate with a significant market share, driven by their effectiveness in targeting specific antigens and their established presence in therapeutics. Polyclonal Antibodies and Bispecific Antibodies follow, contributing to the diversification of therapeutic solutions. Antibody-Drug Conjugates, while smaller in market share, show promising growth due to their innovative approach of combining antibodies with drugs to enhance efficacy and reduce side effects.

The growth trends in this market are propelled by increasing investment in research and development, as well as advancements in technology. The rising prevalence of chronic diseases and an aging population further fuel demand for effective therapeutic solutions. As a result, Antibody-Drug Conjugates are emerging as a significant growth area, attracting attention from biopharmaceutical companies. Innovations in antibody engineering and potential applications in oncology are key drivers for this segment's future.

Monoclonal Antibodies (Dominant) vs. Antibody-Drug Conjugates (Emerging)

Monoclonal Antibodies are highly effective and versatile, making them the dominant force in the South Korea antibody drug-discovery market. Their ability to specifically target antigens leads to successful therapeutic applications across various diseases, including cancers and autoimmune disorders. In contrast, Antibody-Drug Conjugates represent an emerging segment, integrating the specificity of monoclonal antibodies with potent drugs to target disease cells while sparing healthy ones. This dual approach enhances treatment efficacy and minimizes side effects. The innovation behind Antibody-Drug Conjugates positions them as a key player for future growth, appealing to biopharmaceutical companies looking to maximize treatment precision and effectiveness.

### By Technology: Recombinant DNA Technology (Largest) vs. Phage Display Technology (Fastest-Growing)

The market share distribution among the various technologies in the South Korea antibody drug-discovery market reveals that Recombinant DNA Technology holds the largest share, dominating the landscape with its widespread adoption and effectiveness in developing therapeutic antibodies. Following closely, Hybridoma Technology maintains a strong position, while Phage Display Technology is recognized for its rapid growth in recent years, appealing to many research institutions and pharmaceutical companies for its unique advantages.

Growth trends in this segment are significantly driven by advancements in biotechnology and increasing investments in research and development focused on antibody therapies. The demand for novel therapeutic approaches, particularly for cancer and autoimmune diseases, has propelled these technologies forward. Furthermore, collaborations between academic institutions and industry players continue to foster innovation, ensuring these technologies remain at the forefront of drug discovery.

Technology: Recombinant DNA (Dominant) vs. Phage Display (Emerging)

Recombinant DNA Technology is well established within the South Korea antibody drug-discovery market, known for its precision in the synthesis of antibodies that target specific antigens. This dominance is attributed to its robust scalability and efficiency in producing therapeutic proteins. On the other hand, Phage Display Technology, while emerging, is gaining traction due to its ability to rapidly generate diverse libraries of antibodies. Its innovative approach allows for high-throughput screening, making it particularly appealing in the discovery of novel therapeutics. The competition between these two technologies exemplifies the dynamic nature of the market, with Recombinant DNA leading in established applications and Phage Display capturing interest for its pioneering capabilities.

### By Application: Therapeutic Applications (Largest) vs. Diagnostic Applications (Fastest-Growing)

In the South Korea antibody drug-discovery market, Therapeutic Applications dominate the landscape, commanding a significant share. This segment is primarily driven by the increasing prevalence of diseases that require targeted therapies, leading to sustained investments within this area. In contrast, Diagnostic Applications, while smaller in market share, are seeing rapid growth due to advancements in diagnostic technologies and a heightened focus on early disease detection, making it a crucial area for future market dynamics.

The growth trends within these application segments highlight a continuous push towards innovative solutions in antibody drug-discovery. Therapeutic Applications are being propelled by the expanding pipeline of monoclonal antibodies and biotherapeutics, as well as favorable regulatory frameworks. Meanwhile, Diagnostic Applications are evolving swiftly, driven by technological progress and the need for precision medicine. The increased demand for personalized diagnostic tools reflects a shift towards more nuanced and effective healthcare solutions in the region.

Therapeutic Applications (Dominant) vs. Research Applications (Emerging)

Therapeutic Applications have established themselves as the dominant force in the South Korea antibody drug-discovery market, bolstered by robust R&D activities and significant clinical advancements. This segment focuses on developing treatments that target specific diseases, fostering innovations in antibody design and functionality. In contrast, Research Applications are emerging as a vital segment, gaining ground due to the increasing emphasis on antibody characterization and the role they play in drug development. While Therapeutic Applications are synonymous with established market leaders and regulatory support, Research Applications represent a growing interest in utilizing antibodies for various research purposes, indicating a shift towards integrating groundbreaking research methodologies into therapeutic development.

### By End Use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the South Korea antibody drug-discovery market, pharmaceutical companies hold the largest market share, reflecting their established position and extensive resources in drug development. This segment is driven by the growing need for innovative therapeutic solutions and a robust pipeline of antibody drugs. On the other hand, biotechnology companies are emerging rapidly, leveraging advancements in technology and research to capture a significant portion of the market. Their agility and specialization allow them to respond swiftly to market demands. 

The growth trends in this segment are largely influenced by increased R&D investments from both pharmaceutical and biotechnology companies. The rise in chronic diseases and the demand for personalized medicine are key drivers propelling the market forward. Additionally, favorable government policies and funding for research initiatives further enhance the prospects for biotechnology firms, establishing them as pivotal players in the evolving landscape of antibody drug discovery.

Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging)

Pharmaceutical companies dominate the South Korea antibody drug-discovery market due to their extensive experience, financial resources, and established relationships with regulatory authorities. These companies are characterized by a strong commitment to R&D, resulting in a steady flow of innovative drug candidates. In contrast, biotechnology companies are emerging as formidable contenders, focusing on niche areas with cutting-edge technologies to develop novel antibodies. They are often more flexible and innovative than their larger counterparts, allowing for quicker adaptation to new scientific discoveries and market needs. As both segments continue to evolve, their interplay will shape the future landscape of drug discovery, with pharmaceutical companies providing stability and biotechnology firms delivering innovation.

## Competitive Benchmarking

The [antibody drug-discovery](https://www.marketresearchfuture.com/reports/antibody-drug-discovery-market-12055) market in South Korea is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on personalized medicine. Major players such as Roche (CH), AbbVie (US), and Johnson & Johnson (US) are at the forefront, leveraging their extensive research capabilities and The antibody drug-discovery market positions. Roche (CH) emphasizes its commitment to innovation, particularly in monoclonal antibodies, while AbbVie (US) focuses on expanding its oncology portfolio through strategic acquisitions and collaborations. Johnson & Johnson (US) is actively pursuing partnerships with local biotech firms to accelerate the development of novel therapies, thereby shaping a competitive environment that prioritizes cutting-edge solutions and collaborative efforts.
Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The competitive structure is moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of therapeutic options, although the presence of dominant firms like Roche (CH) and AbbVie (US) suggests a concentration of resources and expertise that could shape future developments.
In September 2025, Roche (CH) announced a strategic partnership with a South Korean biotech firm to co-develop a new class of antibody-drug conjugates aimed at treating specific types of cancer. This collaboration not only enhances Roche's local presence but also signifies a commitment to harnessing regional expertise in drug development. The strategic importance of this partnership lies in its potential to expedite the delivery of innovative therapies to the market, thereby reinforcing Roche's competitive edge in the oncology segment.
In October 2025, AbbVie (US) revealed its acquisition of a South Korean biopharmaceutical company specializing in antibody engineering technologies. This acquisition is likely to bolster AbbVie's capabilities in developing next-generation therapeutics, particularly in the field of immuno-oncology. By integrating advanced technologies, AbbVie aims to enhance its product pipeline and maintain its leadership position in the antibody drug-discovery market.
In August 2025, Johnson & Johnson (US) launched a new initiative focused on digital transformation within its research and development processes. This initiative includes the implementation of artificial intelligence (AI) to streamline drug discovery and improve predictive analytics. The strategic importance of this move lies in its potential to significantly reduce time-to-market for new therapies, thereby enhancing Johnson & Johnson's competitive positioning in a rapidly evolving landscape.
As of November 2025, current trends in the antibody drug-discovery market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift underscores the importance of agility and adaptability in a market that is continuously evolving.

## Recent News & Developments

Recent developments in the South Korea Antibody Drug Discovery Market illustrate significant advancements and collaborations among key players. Y Biologics has accelerated its research timelines, focusing on innovative antibody therapies that target autoimmunity and cancer. LG Chem is advancing its pipeline with a strong emphasis on partnerships, notably in co-developing antibody-drug conjugates.

Celltrion has made headlines with promising preliminary results from clinical trials of its bispecific antibody for the treatment of various cancers. KNC Therapeutics is pursuing unique approaches, building strong developmental ties in the local market. In terms of mergers and acquisitions, Samsung Biologics has strategically acquired a start-up to bolster its research capabilities, while Hanmi Pharmaceutical has entered a collaboration with a U.S.-based company to expand its global footprint in antibody discovery.

Market growth has been notably driven by increased funding and government support for biopharmaceutical innovations, with the Ministry of Health and Welfare investing heavily in biotechnology initiatives. Key companies are witnessing elevated market valuations as the sector rapidly evolves, underscoring South Korea's commitment to becoming a leader in antibody drug innovation.

## Report Scope

| MARKET SIZE 2024 | 169.07(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 184.18(USD Million) |
| MARKET SIZE 2035 | 433.67(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.94% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), AbbVie (US), Amgen (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Sanofi (FR) |
| Segments Covered | Type, Technology, Application, End Use |
| Key Market Opportunities | Advancements in personalized medicine drive growth in the antibody drug-discovery market. |
| Key Market Dynamics | Rising investment in Research and Development drives innovation in the antibody drug-discovery market in South Korea. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the antibody drug-discovery market in South Korea?**
A: The market valuation was $169.07 Million in 2024.

**Q: What is the projected market size for the antibody drug-discovery market by 2035?**
A: The projected valuation for 2035 is $433.67 Million.

**Q: What is the expected CAGR for the South Korea antibody drug-discovery market during 2025 - 2035?**
A: The expected CAGR during this period is 8.94%.

**Q: Which companies are the key players in the South Korea antibody drug-discovery market?**
A: Key players include Roche, AbbVie, Amgen, Johnson & Johnson, Merck & Co., Novartis, GSK, Bristol-Myers Squibb, and Sanofi.

**Q: What are the main types of antibodies in the market, and what were their valuations in 2024?**
A: Monoclonal Antibodies were valued at $80.0 Million, Polyclonal Antibodies at $30.0 Million, Antibody-Drug Conjugates at $40.0 Million, and Bispecific Antibodies at $19.07 Million.

**Q: How does recombinant DNA technology compare to other technologies in the market?**
A: Recombinant DNA Technology had a valuation of $30.0 Million, while Hybridoma Technology was valued at $40.0 Million, indicating a competitive landscape.

**Q: What are the therapeutic applications of antibodies, and what were their market values in 2024?**
A: Therapeutic Applications were valued at $80.0 Million, Diagnostic Applications at $40.0 Million, and Research Applications at $49.07 Million.

**Q: What is the market valuation for pharmaceutical companies involved in antibody drug-discovery?**
A: Pharmaceutical Companies had a valuation of $75.0 Million in 2024.

**Q: What role do biotechnology companies play in the antibody drug-discovery market?**
A: Biotechnology Companies were valued at $50.0 Million, highlighting their contribution to the market.

**Q: What is the significance of research institutions in the antibody drug-discovery market?**
A: Research Institutions had a valuation of $44.07 Million, indicating their essential role in advancing antibody research.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-antibody-drug-discovery-market-51921*